Dr. Tarnopolsky, Professor of Pediatrics and Medicine, President and CEO, Exerkine Corporation, and Director of Neuromuscular and Neurometabolic Clinic at McMaster University Medical Center, will discuss exercise and nutrition therapy for mitochondrial disease including:
- the theory and practical issues with endurance and resistance exercise therapy;
- general nutritional guidelines for mitochondrial disease;
- the rationale for the mitochondrial cocktail.
About The Speaker:
Mark Tarnopolsky, MD, PhD, FRDP(C), is the Clinical and Research Director of the Corkins/Lammert Family Neuromuscular and Neurometabolic Clinic at McMaster University. He holds an endowed chair at McMaster Children’s Hospital and Hamilton Health Sciences Foundation in Neuromuscular Diseases and is a Professor of Pediatrics and Medicine. He was co-founder of Life Science Nutritionals (LSN) and Chief Scientific Officer for LSN from 2006-2015. He is the founder (2015) and current president and CEO of Exerkine Corporation. He has received the Dr. David Green Award from the Muscular Dystrophy Association in 2005, the Barsky Lectureship for Excellence in Mitochondrial Medicine in 2007 and the honor award from the Canadian Society for Exercise Physiology 2008, the McMaster Distinguished Alumni Award for Science in 2012, and the International Biochemistry of Exercise Honor Award in 2015. His research focuses on nutritional, exercise, pharmacological, and genetic therapies for neurometabolic (primarily mitochondrial), neuromuscular, and neurogenetic disorders as well as diseases associated with aging. He has authored or coauthored more than 400 scientific articles and many book chapters and abstracts. He has also lectured widely in the area of neurology (neuromuscular and neurometabolic disorders), aging, and exercise physiology. He has served on several editorial and scientific boards (UMDF, MSSE, Mitochondrion, PLOS ONE, Barth Foundation) and has been on Grant Selection Committees for NSERC (Animal Biology, 2003-2006, Chair, 2006), CIHR Biology of Aging Committee (2006), CIHR Movement Committee (2012, 2013, 2015), and Chair of the Emerging Team Grant: Mobility in Aging (2007).
To view the accompanying slides, click here.
For many years, muscle biopsy has been considered the "best" way to obtain an accurate diagnosis of mitochondrial disease. Muscle biopsy is costly, it...
Despite advances in newborn screening and treatment of fatty acid oxidation disorders, patients with very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD) continue to suffer from heart...
Mitochondrial Disease can impact in many ways both an individual and everyone who cares for them: Health care needs Emotional support Basic needs Community...